This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cervical Cancer Treatment Market over the forecast period
The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5834
The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.
Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.
Some of the key players in this market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.
The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.
On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.
On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.
Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.
Radiation Therapy is further segmented into external beam radiation and brachytherapy
Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.
Targeted therapy is further segmented into bevacizumab and pazopanib.
Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.
On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.
Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.
In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.
In the European countries, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.
In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the market.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312